Clinical Trials | March 14, 2026
Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
The endorsement follows overwhelming support for the share swap preceding the merger,
The conflict is also triggering a widening public health emergency
The protections extend through at least 2035, with the potential for further extensions
Subscribe To Our Newsletter & Stay Updated
